Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nialamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.56 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | PRKCG | P05129 | 1/20 | 0.56 |
| ▸ | PRKACA | P17612 | 1/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | AKT1 | P31749 | 1/20 | 0.56 |
| ▸ | GSK3A | P49840 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | PRKX | P51817 | 1/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.56 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nialamide SCHEMBL7324704 | 0.99 | CA1 (0.61) | CA1CA9TDP1ALDH1A1GAA | |
| Nialamide SCHEMBL28086228 | 0.91 | RAB9A (0.55) | CA1CA9TDP1ALDH1A1GAA | |
| Nialamide SCHEMBL7616996 | 0.85 | CYP1A2 (0.66) | CA1CA9TDP1ALDH1A1GAA | |
| SCHEMBL3342974 | 0.83 | GAA (0.66) | ALDH1A1GAAMAPTROCK2RPS6KA5 | |
| SCHEMBL2995747 | 0.83 | CA1 (0.67) | CA1CA9TDP1ALDH1A1GAA | |
| SCHEMBL8248746 | 0.81 | HTT (0.60) | CA1CA9TDP1ALDH1A1GAA | |
| SCHEMBL2995407 | 0.80 | RAB9A (0.72) | CA1CA9TDP1ALDH1A1GAA | |
| SCHEMBL1569194 | 0.80 | ROCK2 (0.82) | CA1CA9ALDH1A1GAAMAPT | |
| Nialamide SCHEMBL1547137 | 0.80 | ALDH1A1 (0.58) | ALDH1A1 | |
| SCHEMBL2999942 | 0.80 | HDAC3 (0.67) | CA1CA9TDP1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5759 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687829-A1 | COMPOSITION FOR CARING FOR KERATIN MATERIALS | L'OREAL (FR) | 2026-02-11 | — | — | EP | claimed |
| US-20260034065-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2026-02-05 | — | — | US | claimed |
| US-20260001942-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H LUNDBECK AS (DK) | 2026-01-01 | — | — | US | claimed |
| WO-2025262247-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H. LUNDBECK A/S (DK) | 2025-12-26 | — | — | WO | claimed |
| US-20250381116-A1 | SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME | OREAL (FR) | 2025-12-18 | — | — | US | claimed |
| US-12472146-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2025-11-18 | — | — | US | claimed |
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | Natural MedTech Pty Ltd (AU) | 2025-11-06 | — | — | US | claimed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4615444-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural Medtech Pty Ltd (AU) | 2025-09-17 | — | — | EP | claimed |
| US-12396982-B2 | Compositions of matter and pharmaceutical compositions | ATAI THERAPEUTICS, INC. (US) | 2025-08-26 | — | — | US | claimed |
| EP-0979271-A1 | VASCULAR ADHESION PROTEIN-1 HAVING AMINE OXIDASE ACTIVITY | Biotie Therapies Ltd. (FI) | 2000-02-16 | — | — | EP | claimed |
| US-6010715-A | SUSTAINED DRUG RELEASE; MONOLITHIC CARRIER | BERTEK, INC. (US) | 2000-01-04 | — | — | US | claimed |
| US-5922341-A | Local administration of pharmacologically active agents to treat premature ejaculation | VIVUS, INCORPORATED (US) | 1999-07-13 | — | — | US | claimed |
| WO-1999013879-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A MONOAMINE OXYDASE INHIBITOR AND THEIR USE IN THERAPY | SANOFI-SYNTHELABO (FR) | 1999-03-25 | — | — | WO | claimed |
| WO-1998053049-A1 | VASCULAR ADHESION PROTEIN-1 HAVING AMINE OXIDASE ACTIVITY | BIOTIE THERAPIES LTD. (FI) | 1998-11-26 | — | — | WO | claimed |
| EP-0563507-B1 | Transdermal patch incorporating a polymer film incorporated with an active agent | BERTEK INC (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0835660-A1 | Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions | Merckx, Gaston Edmond Filomena (BE) | 1998-04-15 | — | — | EP | claimed |
| US-5679373-A | MELT-BLENDING THERMOPLASTIC MATRIX; IMPERMEABLE BACKING; LAMINATION WITHOUT ADHESIVE; CONTROLLED RELEASE | BERTEK, INC. (US) | 1997-10-21 | — | — | US | claimed |
| US-5662926-A | SOLVENT FREE | BERTEK, INC. (US) | 1997-09-02 | — | — | US | claimed |
| EP-0563507-A1 | Transdermal patch incorporating a polymer film incorporated with an active agent | MLI ACQUISITION CORP. II (US) | 1993-10-06 | — | — | EP | claimed |